These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7987844)

  • 1. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line.
    Naredi P; Heath DD; Enns RE; Howell SB
    Cancer Res; 1994 Dec; 54(24):6464-8. PubMed ID: 7987844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells.
    Naredi P; Heath DD; Enns RE; Howell SB
    J Clin Invest; 1995 Mar; 95(3):1193-8. PubMed ID: 7883968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance.
    Zinkewich-Péotti K; Andrews PA
    Cancer Res; 1992 Apr; 52(7):1902-6. PubMed ID: 1551119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells.
    Wasenius VM; Jekunen A; Monni O; Joensuu H; Aebi S; Howell SB; Knuutila S
    Genes Chromosomes Cancer; 1997 Apr; 18(4):286-91. PubMed ID: 9087568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
    Andrews PA; Velury S; Mann SC; Howell SB
    Cancer Res; 1988 Jan; 48(1):68-73. PubMed ID: 3335000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin.
    Chen G; Zeller WJ; Todorov DK
    Anticancer Res; 1993; 13(5A):1269-75. PubMed ID: 8239496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mechanisms for resistance and cross-resistance patterns of cisplatin-resistant tumor lines].
    Tashiro T
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):509-14. PubMed ID: 2321979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Establishment of human ovarian cancer cisplatin resistant cell line COC1/DDP and its mechanism of resistance].
    Zhou Y; Chen H; Yang Q
    Zhonghua Yi Xue Za Zhi; 1996 Sep; 76(9):680-3. PubMed ID: 9275551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
    Mann SC; Andrews PA; Howell SB
    Anticancer Res; 1988; 8(6):1211-5. PubMed ID: 3218956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.
    Yoshida M; Khokhar AR; Siddik ZH
    Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro.
    Jekunen A; Vick J; Sanga R; Chan TC; Howell SB
    Cancer Res; 1992 Jul; 52(13):3566-71. PubMed ID: 1617625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
    Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
    Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the Na+, K(+)-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells.
    Andrews PA; Mann SC; Huynh HH; Albright KD
    Cancer Res; 1991 Jul; 51(14):3677-81. PubMed ID: 1648442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatin-sensitive and resistant human ovarian carcinoma cells.
    Jekunen AP; Hom DK; Alcaraz JE; Eastman A; Howell SB
    Cancer Res; 1994 May; 54(10):2680-7. PubMed ID: 8168097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
    Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
    Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative mapping of platinum and essential trace metal in cisplatin resistant and sensitive human ovarian adenocarcinoma cells.
    Ortega R; Moretto P; Fajac A; Benard J; Llabador Y; Simonoff M
    Cell Mol Biol (Noisy-le-grand); 1996 Feb; 42(1):77-88. PubMed ID: 8833669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.